SLC16A1 and cancer: Previously it has been shown that synthetic mitochondrial targeted silylated derivatives exhibit potent anti-cancer efficacy and hence gave a rationale to develop lipophilic silylates that may exhibit dual MCT1 and mitochondrial inhibitory properties40,41.